GE HealthCare Technologies Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +1.67%.
Did GEHC Beat Earnings? Q2 2025 Results
GE HealthCare delivered a stronger-than-expected second quarter, reporting adjusted EPS of $1.06 against a consensus estimate of $0.92, a beat of 15.51%, while revenue of $5.01 billion edged past expectations by 0.84% and grew 3.5% year over year. The standout driver behind the earnings outperformance was a sharp drop in the effective tax rate, which fell to 18.4% from 24.7% a year ago, alongside lower interest expense, helping net income climb to $486 million from $428 million in the prior-year period. Pharmaceutical Diagnostics was the segment-level highlight, posting 14% revenue growth on rising demand for radiopharmaceutical products, though margin pressure from tariffs weighed on Adjusted EBIT, which slipped to $729 million from $742 million. Despite the profitability headwinds, management raised full-year 2025 guidance meaningfully, lifting adjusted EPS to $4.43 to $4.63 and free cash flow guidance to at least $1.40 billion, reflecting confidence in tariff mitigation progress and healthy underlying capital investment trends, even as shares fell sharply on investor concern over margin contraction.
- Healthy customer investment in capital equipment
- Strong performance in U.S. and EMEA regions
- Increased demand for radiopharmaceutical products including Vizamyl, Cerianna, and Flyrcado
- Lower tax and interest expense boosting EPS
- Lean capabilities and productivity gains partially offsetting tariff impacts
- Book-to-bill of 1.07x with 3% organic orders growth
“We were pleased with solid orders and revenue performance in the second quarter across all segments, reflecting healthy customer investment in capital equipment. We also reported strong earnings performance while leveraging our lean capabilities and demonstrating progress on tariff mitigation. Overall, we believe we are driving long-term value through our strategic priorities and are well positioned operationally.”
GE HealthCare CEO, on the earnings call
Forward Guidance & Outlook
GE HealthCare raised its full-year 2025 guidance: organic revenue growth of approximately 3% (up from 2%–3%); adjusted EBIT margin of 15.2%–15.4% (up from 14.2%–14.4%); adjusted effective tax rate of 20%–21% (down from 21%–22%); adjusted EPS of $4.43–$4.63 (up from $3.90–$4.10), including approximately $0.45 of tariff impact; and free cash flow of at least $1.4 billion (up from at least $1.2 billion). Tariff assumptions include bilateral U.S.-China tariffs rising August 12, 2025, U.S. reciprocal tariffs on EU and Japan at 15% effective August 1, 2025, and increased tariffs on Mexico (30%) and Canada (35%) on August 1, 2025 with USMCA exemptions continuing.
GEHC YoY Financials
GEHC Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.